(EMAILWIRE.COM, December 13, 2018 ) The global plasma fractionation market is projected to reach USD 29.50 Billion by 2023 from USD 21.23 Billion in 2018, at a CAGR of 6.8% during the forecast period. The global plasma fractionation market is consolidated in nature, with top the four players accounting for 60–65% share of the market. In 2017, CSL (Australia), Grifols (Spain), Shire (Ireland), and Octapharma (Switzerland) dominated the plasma fractionation market. These players together accounted for a share of 61.4%.

Ask For Discount: https://www.marketsandmarkets.com/discountreports.asp?id=93798284

CSL (Australia) dominated the plasma fractionation market in 2017. The company’s dominance in the market can be attributed to its diversified product portfolio, which includes a wide range of plasma products for bleeding disorders, neurological diseases, and immune diseases. The company has strong manufacturing and distribution capabilities, which enables it to serve customers across 30 countries with more than 170 plasma collection centers across the US and Europe.

The company continuously focuses on investments in R&D to develop innovative products, strengthen its existing product line, and increase its market share through product launches and emerge as a tough competitor to other leading plasma fractionators. In this regard, the company invested USD 2.0 billion on R&D in the last five years to develop and deliver innovative biotherapies. The company focuses on enhancing its presence in the emerging countries such as India, China, and Brazil. For instance, in August 2017, the company formed a joint venture with Humanwell Healthcare Group (China) to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide), a subsidiary of Humanwell to increase presence in the Chinese plasma fractionation market.

Grifols (Spain) held the second position in the global plasma fractionation market in 2017. Grifols is one of the leaders in plasma collection with a network of 159 plasma donor centers in the US. This helps the company to increase and strengthen its productivity and establish itself as one of the leading producers of plasma-derived products. To increase fractionation capacity further, Grifols has signed an agreement to acquire a 517,000 sq ft plot of land in the Barcelona, Spain by investing USD 1.3 million in July 2016. The development of this land is expected to be completed in 2019.

The company is expected to maintain its leadership position through expansions and collaborations. For instance, in March 2016, the company invested USD 360 million to expand its manufacturing capacity for plasma-derived products. In June 2014, Grifols established a new state-of-the-art facility in Clayton (US). These expansions would strengthen the company’s plasma fractionation capacity and help increase its share in the global market.

Request Bundle Of repoorts: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=93798284

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com